Webinar | May 28, 2021

Engineering Drug Release In EVA Based Implants

Source: Celanese

This webinar covers the Celanese Vitaldose® EVA platform for creating injectable and implantable long-acting drug delivery products. After a quick introduction to Celanese, Dr. Christian Schneider covers the technical basics of the platform technology and outlines how it can be used to deliver small molecules, peptides, and biologics, including some works Celanese has done on predictive modeling of the release of drugs from EVA.

EVA is a low-melting thermoplastic, durable, and water insoluble material that can be processed with active ingredients and formed into shape. EVA is compatible with a wide variety of established manufacturing processes and drug molecules but especially suited for melt-based processing like hot-melt extrusion and co-extrusion, injection molding including micro-molding, film, and tube extrusion. Some EVAs can also be processed via solution casting and coating.

EVAs are excellent drug release and release rate control materials. Due to these properties, EVAs are commonly used to create parenteral long-acting dosage forms with achievable drug release between days up to several years. Well established methods exist to achieve drug release rates close to zero order over extended periods of time utilizing EVA.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online